Skip to main content
UniHealth

Doctor search

Elisabeth Diver, MD

Gynecological Oncology · Brooklyn

NPI 1467776948

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Offices
2
Since medical school
16 years
Graduated 2010

Offices

2 locations · New York University · 5,925 clinicians in this group

Looking this up.

Hospitals listed: NYU Langone Hospitals · Stanford Health Care. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Diver’s office to ask if they take your plan before you enroll.

California Medical Board record

Licence A149779 · Delinquent

Licence status: Delinquent · since 2017 · expires 2025-05-31 · Columbia University College of Physicians and Surgeons.

License renewal fee has not been paid. No practice is permitted.

Matched on the licence number without its letter prefix; check the name before relying on it.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • NYU Langone HospitalsNew York, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of NYU Langone Health, which runs 5 hospitalsHome of Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 75% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 11.9 (10.8 to 13.2) · 2,678 cases, Jan 2024 – Dec 2024Better than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.67 (0.56 to 0.78), Jul 2022 – Jun 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 110.18 (84.1 to 136.26) · 561 cases, Jul 2022 – Jun 2024Better than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 2.66 (1.81 to 3.51) · 16,112 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 3.24 (1.36 to 5.12) · 9,218 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 2.56 (1.28 to 3.83) · 9,540 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.39, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.097, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.529, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.7 (3.1 to 4.4) · 2,678 cases, Jan 2024 – Dec 2024Better than the national rate — Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies): 10.5 (9.1 to 12.3) · 10,521 cases, Jan 2022 – Dec 2024Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.7 to 0.8) · 6,063 cases, Jan 2024 – Dec 2024
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for NYU Langone Hospitals

Behind the star rating — Deaths: 8 better, 0 the same, 0 worse of 8 measures. Safety: 5 better, 2 the same, 1 worse of 8 measures. Readmissions: 8 better, 1 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at NYU Langone Hospitals
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits11.9 (10.8 to 13.2) · 2,678 casesWorseJan 2024 – Dec 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.67 (0.56 to 0.78)BetterJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths110.18 (84.1 to 136.26) · 561 casesBetterJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths2.66 (1.81 to 3.51) · 16,112 casesBetterJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths3.24 (1.36 to 5.12) · 9,218 casesBetterJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths2.56 (1.28 to 3.83) · 9,540 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.291BetterOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.39BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.097BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.529BetterOct 2024 – Sep 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits3.7 (3.1 to 4.4) · 2,678 casesBetterJan 2024 – Dec 2024
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits10.5 (9.1 to 12.3) · 10,521 casesBetterJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.7 to 0.8) · 6,063 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.48 (0.95 to 2.01) · 9,995 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 331 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths5.2 · 532 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths6.7 · 547 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths5.2 · 2,910 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths8 · 4,115 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths7.4 · 1,351 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths1.6 · 23,286 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0.01 to 0.24) · 48,461 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.23 (0.12 to 0.34) · 50,693 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.38 (0.66 to 2.11) · 9,390 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.79 (0.99 to 2.59) · 12,979 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.62 (0.53 to 2.72) · 3,510 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.6 (0.38 to 0.82) · 40,829 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths2.8 · 3,298 casesNoneApr 2023 – Mar 2025
SSI - Abdominal HysterectomyInfections1.091No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.859No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.3 · 667 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits18.7 · 4,060 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-23.8 · 603 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-22.8 · 3,334 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.5 · 4,338 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.4 · 5,069 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits3.7 · 3,383 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits6.8 · 386 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.7 · 820 casesNoneJul 2023 – Jun 2025

What patients said (10,034 patients answered, 23% of those asked)

Patient survey stars by topic at NYU Langone Hospitals
Cleanliness3
Nurse communication4
Doctor communication3
Communication about medicines3
Discharge information3
Overall hospital rating4
Quietness2
Recommend hospital4
Share of patients giving the best answer at NYU Langone Hospitals
Room was "always" clean70%
Nurses "always" communicated well80%
Doctors "always" communicated well79%
Staff "always" explained62%
Yes, staff "did" give patients this information86%
Yes, staff "did" give patients information about help after discharge85%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully77%
Doctors "always" treated them with courtesy and respect84%
Patients who gave a rating of "9" or "10" (high)72%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night49%
"YES", patients would definitely recommend the hospital75%
Staff "always" explained possible side effects48%
Yes, staff "did" give patients information about possible symptoms88%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Medicaid work

$1,461 in 2021

Medicaid paid $1,461 for 38 billed services this clinician did in 2021, up to 13 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2021
Long return visit (40+ min)13$804
Short return visit (20+ min)25$657
Medicaid work by year
202138213$1,461
202026112$718
201912112$307
See the largest Medicaid services in earlier years

2020

Largest Medicaid services in 2020
Short return visit (20+ min)26$718

2019

Largest Medicaid services in 2019
Short return visit (20+ min)12$307

Drugs they prescribed that Part D paid

$24,745

Pharmacies billed $24,745 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

23 generic and fewer than 11 brand-name prescriptions · $24,745 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Year by year

Part D prescribing by year
20242411NoneNone$24,745
202260180% (0)None$7,913
202110423None20%$26,024
20207124None21%$53,807
201912429NoneNone$260,883
201814538NoneNone$83,597
201746NoneNoneNone$3,544
20162614NoneNone$260
201418NoneNoneNone$904
20133915None51%$2,152

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2021: 3 drugs

Part D drugs prescribed in 2021
Eliquis14$7,441$531
Ondansetron18$277$15
Metoclopramide13$22$2

2020: 1 drug

Part D drugs prescribed in 2020
Eliquis11$5,477$498

2019: 2 drugs

Part D drugs prescribed in 2019
Afinitor15$248,445$16,563
Ondansetron13$49$4

2018: 3 drugs

Part D drugs prescribed in 2018
Ondansetron14$265$19
Ibuprofen17$76$4
Metoclopramide12$53$4

2013: 1 drug

Part D drugs prescribed in 2013
Jolivette11$248$23

Money from drug and device companies

$51 in 2025

Industry payments by year
202522None$51
202411None$17
202134$8,057$8,057
202011$1,300$1,300
201936$2,000$2,247

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Karyopharm TherapeuticsXpovio$33
1 payment
  • Meals for Xpovio · 2025-05-30 · $33
Vertex PharmaceuticalsJournavx$18
1 payment
  • Meals for Journavx · 2025-02-25 · $18
See all 2 published payments
Every published payment
Karyopharm TherapeuticsMeals · 2025-05-30Xpovio$33
Vertex PharmaceuticalsMeals · 2025-02-25Journavx$18
See earlier years (2024, 2021, 2020, 2019)

2024: $17

Payments by company in 2024
Vertex PharmaceuticalsNone$17
1 payment
  • Meals · 2024-11-19 · $17

2021: $8,057

Payments by company in 2021
GlaxoSmithKlineZejula$5,200
2 payments
  • Consulting · 2021-04-14 · $3,250
  • Consulting for Zejula · 2021-02-04 · $1,950
Novartis PharmaceuticalsKisqali$2,167
1 payment
  • Consulting for Kisqali · 2021-11-16 · $2,167
EMD SeronoNone$690
1 payment
  • Consulting · 2021-09-13 · $690

2020: $1,300

Payments by company in 2020
GlaxoSmithKlineZejula$1,300
1 payment
  • Consulting for Zejula · 2020-01-14 · $1,300

2019: $2,247

Payments by company in 2019
Clovis OncologyRubraca$2,101
3 payments
  • Meals for Rubraca · 2019-03-15 · $85
  • Meals for Rubraca · 2019-03-15 · $16
  • Consulting for Rubraca · 2019-03-15 · $2,000
Merck Sharp & DohmeLynparza$130
2 payments
  • Meals for Lynparza · 2019-10-21 · $65
  • Meals · 2019-09-25 · $65
TesaroZejula$17
1 payment
  • Meals for Zejula · 2019-02-07 · $17

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
TESARO, Inc. · Phase 2 Multicohort Study To Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer Opal · 2019Their institution$345,953
GlaxoSmithKline, LLC. · A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab · 2022Their institution$156,829
EMD Serono, Inc. · Safety Study of Bintrafusp Alfa in Combination With Platinum + Paclitaxel Bevacizumab and Bintrafusp Alfa in Combination With Platinum + Radiation Therapy in Participants With Advanced Cervical Cancer · 2021Their institution$143,231
GlaxoSmithKline, LLC. · A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab · 2024Their institution$117,564
GlaxoSmithKline, LLC. · A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab · 2021Their institution$86,124
GlaxoSmithKline, LLC. · A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab · 2020Their institution$27,650
GlaxoSmithKline, LLC. · Phase 2 Multicohort Study To Evaluate the Safety and Efficacy of Novel · 2020Their institution$9,653
GlaxoSmithKline, LLC. · A Phase 1b/2 Multicohort Umbrella Study To Evaluate the Safety and Eff · 2022Their institution$8,757
GlaxoSmithKline, LLC. · A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab · 2025Their institution$6,662
GlaxoSmithKline, LLC. · A Phase 1b/2 Multicohort Umbrella Study To Evaluate the Safety and Eff · 2021Their institution$2,005

Professional record

NPI
1467776948
Licence
CA 149779California A149779: Delinquent · expires 2025-05-31
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
Yes
Taxonomy
Federal specialty code 207VX0201X (207VX0201X)
Mailing address
900 Blake Wilbur Dr, Palo Alto, CA, 94304
NPI first listed
2010-03-26
NPI last updated
2017-08-07

This is when the NPI record was last certified, not a medical board exam.